Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled RV1729 in COPD
NCT02140346Phase 1Completed
- Sponsor
- RespiVert
- Start
- Aug 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RV1729 in chronic obstructive pulmonary disease (COPD) (2 cohorts), sponsored by RespiVert. Primary endpoints: Incidence of treatment emergent adverse events at 56 days, ECG assessment (12 lead ECG) at 56 days and 5 more. Started Aug 2014; status: completed.
02
Drugs
RV1729
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02140346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140346.